CVRx, Inc.
Close on Oct 19, 2026
- Market cap
- $35.80M
- P/E (TTM)
- –
- Dividend yield
- –
Earnings
Next report expected Nov 4, 2026, after market close (estimated from past report dates)
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q2 FY2026 Ended Jun 30, 2026 | Aug 6, 2026 | After market close | $15.70M | $-0.53 | – |
| Q1 FY2026 Ended Mar 31, 2026 | Apr 13, 2026 | Before market open | – | – | – |
| Q4 FY2025 Ended Dec 31, 2025 | Feb 12, 2026 | After market close | $16.00M | $-0.46 | – |
| Q3 FY2025 Ended Sep 30, 2025 | Nov 5, 2025 | After market close | $14.70M | $-0.49 | – |
| Q2 FY2025 Ended Jun 30, 2025 | Aug 4, 2025 | After market close | $13.60M | $-0.57 | – |
| Q1 FY2025 Ended Mar 31, 2025 | Apr 7, 2025 | After market close | $12.30M | – | – |
| Q4 FY2024 Ended Dec 31, 2024 | Jan 13, 2025 | Before market open | – | – | – |
| Q3 FY2024 Ended Sep 30, 2024 | Oct 29, 2024 | After market close | $13.40M | $-0.57 | – |
| Q2 FY2024 Ended Jun 30, 2024 | Jul 29, 2024 | After market close | – | – | – |
| Q1 FY2024 Ended Mar 31, 2024 | Apr 30, 2024 | After market close | – | – | – |
| Q4 FY2023 Ended Dec 31, 2023 | Jan 8, 2024 | Before market open | – | – | – |
Company guidance
Outlook given with results on Aug 6, 2026, compared with the previous outlook
| Measure | Period | Guidance | vs. prior |
|---|---|---|---|
| Gross margin | full year of 2026 | 86% to 87% | Raised |
| Operating expenses | full year of 2026 | $99.00M to $101.00M | Lowered |
| Total revenue | full year of 2026 | $58.00M to $60.00M | Lowered |
| total revenue | third quarter of 2026 | $13.50M to $14.50M | New |
Figures and the sentence they come from are taken from the company's earnings release. Hover a measure to read the source sentence.
Press releases
Announcements CVRx filed with the SEC
CVRx Reports Second Quarter 2026
Results of operations · EX-99.1 to Form 8-K
CVRx Reports First Quarter 2026 Financial
Results of operations · EX-99.1 to Form 8-K
Preliminary First Quarter 2026 Financial Results
Results of operations · Other events · EX-99.1 to Form 8-K
CVRx Reports Fourth Quarter and Full
Results of operations · EX-99.1 to Form 8-K
CVRx Reports Preliminary Fourth Quarter and
Material agreement · Results of operations · New financial obligation · Other events · EX-99.1 to Form 8-K
Third Quarter 2025 Financial and Operating Results
Results of operations · EX-99.1 to Form 8-K
CVRx Reports Second Quarter 2025 Financial and Operating Results
Results of operations · Executive or director change · EX-99.1 to Form 8-K
First Quarter 2025 Financial and Operating Results
Results of operations · EX-99.1 to Form 8-K
Preliminary First Quarter 2025 Financial Results
Results of operations · EX-99.1 to Form 8-K
Fourth Quarter and Full Year 2024 Financial and Operating Results
Results of operations · EX-99.1 to Form 8-K
Preliminary Fourth Quarter and Fiscal Year 2024 Financial Results and Issues Fiscal 2025 Guidance
Results of operations · Other events · EX-99.1 to Form 8-K
CVRx Reports Third Quarter 2024 Financial and
Results of operations · EX-99.1 to Form 8-K
CVRx Reports Second Quarter 2024 Financial and
Results of operations · EX-99.1 to Form 8-K
CVRx Reports First Quarter 2024 Financial and
Results of operations · Executive or director change · EX-99.1 to Form 8-K
CVRx Reports Fourth Quarter and Full Year 2023
Results of operations · EX-99.1 to Form 8-K
Preliminary Fourth Quarter and Fiscal Year 2023 Financial Results and Announces Nadim Yared Retirement Plans
Results of operations · Executive or director change · Other events · EX-99.1 to Form 8-K
CVRx receives FDA approval for expanded labeling
Other events · EX-99.1 to Form 8-K
CVRx Reports Third Quarter 2023 Financial and
Results of operations · EX-99.1 to Form 8-K
CVRx Reports Second Quarter 2023 Financial and
Results of operations · EX-99.1 to Form 8-K
43rd Annual William Blair Growth Stock Conference,
Shareholder vote results · Regulation FD disclosure · EX-99.1 to Form 8-K
CVRx Reports First Quarter 2023 Financial and
Results of operations · EX-99.1 to Form 8-K
Totality of Evidence from BeAT-HF Study Shows
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
regarding our future financial performance, our anticipated growth strategies, anticipated trends in our industry, our
Regulation FD disclosure · Other events · EX-99.2 to Form 8-K
Reports Preliminary Results of the BeAT-HF Post-Market Randomized Clinical Trial
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
CVRx Reports Fourth Quarter and Full Year 2022
Results of operations · EX-99.1 to Form 8-K
CVRx Reports Preliminary Fourth Quarter and Fiscal Year 2022 Financial Results
Results of operations · EX-99.1 to Form 8-K
CVRx Reports Third Quarter 2022 Financial and
Material agreement · Results of operations · New financial obligation · EX-99.1 to Form 8-K
CVRx Reports Second Quarter 2022 Financial and
Results of operations · EX-99.1 to Form 8-K
CVRx Reports First Quarter 2022 Financial and
Results of operations · EX-99.1 to Form 8-K
CVRx Reports Fourth Quarter and Full Year 2021
Results of operations · EX-99.1 to Form 8-K
Reports Preliminary Fourth Quarter and Fiscal Year 2021 Financial Results
Results of operations · EX-99.1 to Form 8-K